# Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

> **NCT07003022** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 40 (estimated)

## Conditions studied

- Colo-rectal Cancer
- MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

## Interventions

- **DRUG:** cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib.

## Key facts

- **NCT ID:** NCT07003022
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07003022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07003022, "Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07003022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*